Mesenchymal stromal cell therapy for liver diseases

Area of Science:

• * Regenerative Medicine
• * Immunology
• * Hepatology

Background:

• * Mesenchymal stromal cells (MSCs) possess immunosuppressive properties and secrete trophic factors beneficial for liver fibrosis treatment.
• * Clinical and preclinical studies explore MSCs for liver fibrosis, though mechanisms require further characterization.
• * MSC-secreted factors are vital for liver regeneration, reducing inflammation, apoptosis, and fibrosis while promoting angiogenesis.

Purpose of the Study:

• * To review the safety, efficacy, and therapeutic effects of MSC transplantation in liver fibrosis patients.
• * To explore potential routes for MSC transplantation in liver disease.
• * To discuss methods for enhancing MSC functionality for improved therapeutic outcomes.

Main Methods:

• * Comprehensive literature review of clinical and preclinical studies on MSCs for liver fibrosis.
• * Analysis of safety and efficacy data from MSC transplantation studies.
• * Examination of strategies to enhance MSC therapeutic potential.

Main Results:

• * MSCs demonstrate therapeutic effects in liver fibrosis by modulating inflammation and promoting regeneration.
• * Various trophic factors secreted by MSCs contribute significantly to liver repair.
• * Enhanced MSC functionality through sorting, priming, or genetic engineering shows promise.

Conclusions:

• * MSC transplantation is a promising therapeutic strategy for liver fibrosis, leveraging immunosuppression and trophic factor secretion.
• * Further research into optimizing MSC transplantation routes and enhancing cell function is warranted.
• * MSC-based therapies offer a potential avenue for improving outcomes in patients with liver fibrosis.